Stress Echocardiography

Eugenio Picano

Stress Echocardiography

Fifth, Completely Revised and Updated Edition

Springer

Eugenio Picano MD, PhD
Director General
Institute of Clinical Physiology of Pisa
National Research Council
1st Fisiologia Clinica
Via G. Moruzzi, 1
56124 Pisa
Italy

ISBN: 978-3-540-76465-6 e-ISBN: 978-3-540-76466-3

DOI: 10.1007/978-3-540-76466-3

Library of Congress Control Number: 2008940140

Cover design: Frido Steinen-Broo, eStudio Calamar, Spain

Printed on acid-free paper

9 8 7 6 5 4 3 2 1

springer.com

Preface

This book has a past. Its various editions parallel the growth of stress echocardiography within the scientific community and the clinical arena. The first edition in 1991 consisted of 100 pages, which increased to 200 in the second (1994), 300 in the third (1997), nearly 500 pages in the fourth, and finally more than 600 in the current fifth edition. The general perception of stress echocardiography has changed in the cardiology community. No longer a promising innovation viewed with a mixture of suspicion and attraction, it is now an established technique with the huge potential to resolve the present paradox of saving health care money while at the same time improving diagnostic standards. In a cardiological climate where inappropriate, redundant, and often risky imaging examinations proliferate, stress echocardiography offers the great advantage of being relatively low cost, free of biohazards for the patient, and causing no ecological stress on the planet. By choice and by necessity, modern, responsible diagnosis with cardiac imaging must be economical, ecological, and therefore usually echocardiographic. Another major change has taken place in stress echocardiography laboratories during the last 5 years, making a new edition of the book mandatory. For a long time, the scope and application of stress echocardiography remained focused on coronary artery disease. In the last few years, it has exploded in its breadth and variety of applications, enjoying the tremendous technological and conceptual versatility that this technique offers. Nowadays, in the stress echocardiography laboratory we assess not only left ventricular function, but also coronary artery flow, valve gradients, intraventricular pressures, and pulmonary hemodynamics. We stress not only coronary arteries, but also the valves, myocardium, vessels, alveolar–capillary barrier in the lung, and peripheral and pulmonary circulation. Ten years ago, only patients with known or suspected coronary artery disease entered the stress echocardiography laboratory, and only regional wall motion was assessed. Now, we evaluate coronary artery disease as well as cardiomyopathy, valvular heart disease, children with congenital heart disease, and patients with incipient or advanced vascular disease. For each patient, we can tailor a dedicated stress with a specific method to address a particular diagnostic question. Thirty years ago, Harvey Feigenbaum – one of the founding fathers of modern echocardiography – stated that it is not possible to understand the cardiac patient without the help of resting transthoracic echocardiography. After 30 years, we can safely state that it is not possible to understand the cardiac patient without the help of stress echocardiography. The book was single authored in the first edition, and then enjoyed many distinguished contributors in its subsequent editions, up to the record number of 29 contributors in the present edition. They come from 15 countries spanning four continents and represent, in

my opinion, some of the best available knowledge and expertise in their respective fields. I am proud and honored that they accepted the invitation to be a part of this project. At the same time, I aimed to avoid the fragmentation, gaps, and inconsistencies of a multiauthor text; therefore, I painfully decided to draft the first version of each chapter – then asked for corrections, revisions, cuts, additions, and integrations from more knowledgeable contributors. To all of them and to the junior and senior colleagues who have worked with me over the last 30 years – far too many to be mentioned here – *grazie*.

Pisa, February 2009 **Eugenio Picano**

Contents

List of Contributors

Giorgio Arpesella
Dipartimento Cardiovascolare
Universitá di Bologna
Via Massarenti 9
40138 Bologna, Italy

Gigliola Bedetti
Cardiology Division
Imola Hospital
Via Montericco 4
40026 Imola, Italy

Tonino Bombardini
Associate Researcher
Istituto di Fisiologia Clinica
CNR, Via Moruzzi 1
56124 Pisa, Italy

Robert Bonow
Goldberg Professor of Medicine
Division of Cardiology
Northwestern University's Feinberg
School of Medicine
676 St., Claire St., Suite 600
Chicago, IL 60611, USA

Adrian C. Borges
Medizinische Klinik für Kardiologie
und Angiologie, Campus Mitte
Charité – Universitätsmedizin
Schumannstr 20/21
10117 Berlin, Germany

Paolo G. Camici
Division of Clinical Sciences
Hammersmith Hospital
MRC Clinical Sciences Centre
London SW7 2AZ, UK

Rodolfo Citro
Cardiology Imaging Unit
San Luca Hospital
Via F Cammarota
Vallo della Lucania
Salerno 84048, Italy

Lauro Cortigiani
Cardiac Imaging Lab, Lucca Hospital
"Campo di Marte"
Via dell'Ospedale 238
55100 Lucca, Italy

Kwan Damon
Division of Cardiology,
Department of Medicine
San Francisco Veterans Affairs Hospital
University of California San Francisco
San Francisco, CA 94143-0214, USA

Maurizio Galderisi
Department of Clinical
and Experimental Medicine
Federico II University Hospital
Cardiology Unit
Via Sergio Pansini, 5
80131 Naples Italy

Ekkehard Grünig
Pulmonary Hypertension Unit
Department of Cardiology and
Pneumology
University Hospital Heidelberg
INF 410
69120 Heidelberg, Germany

Michael Henein
Cardiology Department
Heart Centre University Hospital
90185 Umea, Sweden

Patrizio Lancellotti
Department of Cardiology
University Hospital Sart Tilman
CHU Sart Tilman B35
4000 Liège, Belgium

Jorge Lowenstein
Cardiodiagnostic Department
Investigaciones Médicas
Viamonte 1871, CP 1056
Buenos Aires, Argentina

Thomas H. Marwick
University of Queensland
Princess Alexandra Hospital
Brisbane
Queensland 4000, Australia

Mark J. Monaghan
Department of Cardiology,
King's College Hospital
Denmark Hill
London SE5 9RS, UK

Jean-Luc Monin
Department of Cardiology
Assistance Publique-Hôpitaux de Paris
Henri Mondor Hospital
51 avenue De Lattre de Tassigny
94010 Créteil, France

Miodrag Ostojic
Cardiology Department
University of Belgrade
Belgrade Medical School
Koste Todorovica 8
11000 Belgrade, Serbia

Philippe Pibarot
Laval Hospital Research Center
Québec Heart Institute
Laval University
2725, Chemin Sainte-Foy
Québec, G1V-4G5, Canada

Luc A. Piérard
Department of Cardiology
University Hospital Sart Tilman B-35
4000 Liège, Belgium

Fabio Recchia
Scuola Superiore Sant'Anna
Piazza Martiri della Libertà 33
56127 Pisa, Italy

Fausto Rigo
Dipartimento Cardiovascolare
Ospedale Civile di Mestre
Via Ospedale
30170 Venezia (VE), Italy

Alberto San Román
Department of Cardiology
Instituto de Ciencias del
Corazón (ICOCOR),
Hospital Clnico
Ramón y Cajal, 3
47005 Valladolid, Spain

Nelson B. Schiller
Division of Cardiology
Department of Medicine, Box 0214
San Francisco Veterans Affairs Hospital
University of California San Francisco
San Francisco, CA 94143-0214, USA

Juerg Schwitter
University Hospital Zurich
Clinic of Cardiology and
Cardiac MR Center
Raemistrasse 100
CH-8091 Zurich, Switzerland

Rosa Sicari
Institute of Clinical Physiology
CNR
Via Moruzzi, 1
56124 Pisa, Italy

Jae-Kwan Song
Echo Laboratory, Asan Medical Center
Department of Pulmonary and
Critical Care Medicine,
Asan Medical Center, University of Ulsan
College of Medicine, 388-1,
Pungnap-2dong, Songpa-gu
Seoul, Republic of Korea

William Wijns
Cardiovascular Center
OLV Hospital, Moorselbaan 164
9300 Aalst, Belgium

Section 1

Basic Principles, Methodology and Pathophysiology

Stress Echocardiography: A Historical and Societal Perspective

1

Eugenio Picano

Like many scientific innovations, in the last 30 years stress echocardiography has evolved from the status of "promising technique," embraced by a few enthusiastic supporters [1, 2] amid general skepticism [3], to "established technology" [4] accepted by the overwhelming majority of cardiologists [5], to finally play a pivotal role in general cardiology [6, 7] with specialty echocardiography guidelines [8, 9] (Fig. 1.1). An astounding increase in the amount of editorial space devoted to stress echocardiography in major journals and meetings testifies to its greater acceptance by cardiologists (Fig. 1.1) and to the progressive expansion of the diagnostic domain, from coronary artery disease to its currently increasing role in the characterization of cardiomyopathy and valvular heart disease patients [10] (Fig. 1.2). The growth of this technique can be schematically staged by decade, grossly corresponding to three major technological step-ups: its infancy, as a monodimensional approach only applied with exercise during the 1970s; adolescence, characterized by two-dimensional echocardiography technology also applied with pharmacological stresses in the 1980s; young adulthood, when the methodology was reshaped with the addition of coronary flow reserve to standard wall motion analysis; and full maturity today, with deployment of the technique in the clinical arena to minimize the iatrogenic, legal, and social burdens that accompany the use of complementary and competing ionizing techniques such as scintigraphy and multislice computed tomography (MSCT) (Fig. 1.3).

1.1 Dawn of the Stress Echocardiography Era: From Experimental Studies to the Monodimensional Approach

In 1935, Tennant and Wiggers showed that coronary occlusion resulted in almost instantaneous abnormality of wall motion [11]. Experimental studies performed some 40 years later with ultrasonic crystals [12] and two-dimensional echocardiography [13] on a canine model proved that during acute ischemia [12] and infarction [13] reductions in regional flow are closely mirrored by reductions in contractile function, setting the stage for the clinical use of ultrasonic methods in ischemic heart disease. The monodimensional (*M*-mode) technique

E. Picano, *Stress Echocardiography*,



Fig. 1.1 The life cycle of a medical innovation, from promising technique (stress echocardiography in the 1980s) to established technology (stress echocardiography in the last 10 years). Various applications of stress echocardiography are all simultaneously present in today's stress echocardiography laboratory, but at different stages of maturity. The qualitative assessment of regional wall motion abnormalities for detection of coronary artery disease is clearly "established", but coronary flow reserve is still in the "early adopter" phase, while other applications (such as tissue characterization or myocardial velocity imaging with tissue Doppler or strain rate) have been discarded after the validation process and are now obsolete or have been abandoned for current clinical applications of stress echocardiography



Fig. 1.2 Stress echocardiography vital signs: the editorial golden age. *y-axis* indicates the number of published articles on stress echo; the *x-axis* indicates the year. DCM = dilated cardiomyopathy; CAD = coronary artery disease (From Medline Healthgate)



Fig. 1.3 The timeline of innovation in stress echocardiography. Quantum leaps in clinical impact are linked to technological improvements and cultural advancement. CFR = coronary flow reserve

was the only one available to cardiologists in the 1970s and nowadays appears largely inadequate for providing quality information when diagnosing myocardial ischemia. The time-motion technique sampling, according to an "ice-pick" view, greatly limited exploration to a small region on the left ventricle. Although this feature could hardly be reconciled with the strict regional nature of acute and chronic manifestations of ischemic heart disease, for the first time the monodimensional technique outlined echocardiography's potential in diagnosing transient ischemia. The very first reports describing echocardiographic changes during ischemia dealt with the use of *M*-mode in two different models of exercise-induced ischemia [14] and spontaneous vasospastic angina [15]. Landmark studies by Alessandro Distante of the Pisa echo laboratory recognized transient dyssynergy to be an early, sensitive, specific marker of transient ischemia, clearly more accurate than electrocardiogram (ECG) changes and pain (Fig. 1.4). The potential clinical impact of these observations became more obvious with the advent of the two-dimensional technique, which allowed exploration of all segments of the left ventricle with excellent spatial and temporal resolution, and was, therefore, ideally suited for searching for the regional and transient manifestations of myocardial ischemia. If the monodimensional technique was a bludgeon, then the two-dimensional technique was a bow – a more potent weapon, and much easier to use.

1.2 Second-Generation Stress Echocardiography: Pharmacological Stresses in the 2D Era

Once armed with the bow – the 2D technique – stress echocardiographers now had to find the arrows – the proper stresses. Exercise, although already on hand, was soon revealed to be a blunt arrow: what was the "mother of all tests" for the cardiologist was



Fig. 1.4 Coronary angiographic (*upper panels*) and echocardiographic monodimensional tracings (*lower panels*) during attacks of variant angina induced by ergonovine maleate. At baseline, left anterior descending coronary artery shows a tight stenosis (*left panel*); the artery is totally occluded by a complete vasospasm during ischemia (*middle panel*); and it is again open in the recovery phase (*right panel*). The corresponding three frames of an original *M*-mode recording document a fully reversible sequence of myocardial ischemia. The septum moves normally at rest (*left panel*) and is obviously akinetic during ischemia (*middle panel*). During the recovery phase (*right panel*), the previously ischemic wall exhibits a significant overshoot in motion and systolic thickening. (From [15])

at that time a disagreeable "stepmother" for the echocardiographer due to the technical difficulties and degraded quality of echocardiographic imaging during exercise. The problem was minimized with posttreadmill imaging, still the standard in the USA today [16]. An alternative approach, more popular in Europe, was the introduction of pharmacological stress echocardiography detecting myocardial ischemia [17] and viability [18].

In the late 1980s, multiple generations of ultrasound equipment evolved very rapidly, boosting image quality and offering the ability to image almost any patient. In two-dimensional exercise echocardiography, stress echocardiography sometimes was a "guess gram" (Fig. 1.5) and torture for the eyes. It was often repeated by eminent opinion leaders that you needed "magic eyes" and "magic machines" to obtain good results. The technique divided the echocardiographic community into two camps, "believers" and "skeptics"



Fig. 1.5 Stress echocardiography in its infancy: not easy on the eyes. Exercise echocardiograms are shown before (*left panel*) and after (*right panel*) coronary artery bypass surgery. At that time (1979), image quality was so poor that even obtaining a single "typical example" for publication purposes was a challenge. (From [16])

[3, 4], and never attained extensive clinical application. Things changed rapidly in the mid-1980s, with the evolution of imaging technology and the advent of pharmacological stresses, which were less technically challenging than exercise. In the 1990s, thanks to this methodological evolution, the technique was upgraded from research toy to clinical tool. The widespread use of this technique received wide-scale support and credibility; prospective multicenter studies provided effectiveness [19] and safety [20] data with pharmacological stress echocardiography. The same groups that proposed stress echocardiography in journals and meetings now introduced the technique into their clinical practice. Rather than the number of published articles, it was this compelling argument that convinced most laboratories to implement stress echocardiography in their own practice as well; the world described in journals eventually came to resemble real-life cardiology (Fig. 1.6).

1.3 Third-Generation Stress Echocardiography Today: Coronary Flow Reserve and Dual Imaging

For 20 years, throughout the 1980s and the 1990s, stress echocardiography remained virtually unchanged [1, 4, 5]. Certainly, there were obvious, continuous, subtle improvements in imaging technology. Digital echocardiographic techniques permitted the capture and synchronized display of the same view at different stages. The introduction of native tissue harmonic imaging, which increases lateral resolution and signal-to-noise ratio, clearly improved endocardial border detection. Intravenous contrast echocardiography with second-generation lung-crossing agents for endocardial border recognition allowed



Fig. 1.6 The birth of pharmacological stress echo. End-diastolic (*upper panels*) and end-systolic (*lower panels*) frames at baseline (*left panel*), during early hyperkinetic phase (*middle panel*, 1 min postdipyridamole infusion), and 3 min postdipyridamole infusion at peak ischemic effect (*right panel*) showing septal akinesia. The quality of the image (compared to Fig. 1.5) is dramatically improved thanks to the evolution of technology and the use of pharmacological instead of posttreadmill exercise echo. (Original images from [17])

cardiologists to study otherwise "acoustically hostile" patients and segments [8, 9]. To be honest, however, the last 20 years were also disappointing with regard to the three great unfulfilled promises of stress echocardiography: tissue characterization of the myocardial structure (scar vs. normal tissue); myocardial perfusion with myocardial contrast echocardiography (allowing perfusion to be coupled with function in the same stress); regional wall motion quantification with myocardial velocity imaging methods (turning the diagnosis of regional wall motion from an opinion into a quantifiable unit). At first, each of these targets appeared to be within reach, based on strong experimental data and encouraging clinical experiences, but they did not pass the test of multicenter studies and to date have not revealed any valuable clinic impact [8, 9]. Each of these objectives – tissue structure, myocardial perfusion, and regional function quantification – can be realized in a more effective and reproducible way with cardiovascular magnetic resonance (CMR) – with delayed contrast enhancement for scar detection, contrast imaging for myocardial perfusion, and tagging for wall motion objective quantification [5]. However, in the last 5 years, a major innovation changed the face and the diagnostic content of stress echocardiography: dual imaging of wall motion and coronary flow reserve with pulsed-Doppler imaging of the middistal left anterior descending coronary artery [21–23]. Imaging coronary flow reserve dramatically expands the prognostic potential of stress echocardiography, since in the absence of wall motion negativity, the patient subset with reduced coronary flow reserve has a less benign outcome and in patients with wall motion abnormality, those with reduced coronary flow reserve also have a more malignant prognosis (Fig. 1.7) [22, 23]. In the same



Fig. 1.7 The magical world of coronary flow reserve enters the stress echocardiography laboratory with pulsed Doppler, which allows assessment of coronary flow reserve on the middistal left anterior descending artery (visualized by color Doppler on *upper panel*). In this case, there is a normal coronary flow reserve, with a >2.5-fold increase in coronary flow velocity during stress (*right lower panel*) compared with rest (*left lower panel*). LAD, left anterior descending; PW, Pulsed Wave Doppler. (By courtesy of Fausto Rigo, Venice-Mestre [21])

setting, with the same stress, it is now possible to image function and flow simultaneously, and therefore catch two "birds" (flow and function) with one "stone" (vasodilator stress). Although coronary flow reserve is a technology-in-progress and has yet to reach its full maturity, it is now considered a new standard in the clinical application of stress echocardiography [24]. However, once again this quantum leap in the impact of stress echocardiography was the result of a conceptual rather than a technological step-up during the last 5 years: that is, the need to incorporate long-term radiation risk in the risk–benefit assessment of competing imaging techniques [5]. Medical, legal, and social arguments have boosted the use of stress echocardiography as the best way to optimize the risk–benefit ratio for the individual patient, minimize the risk of litigation due to unjustified long-term cancer risk, and nullify the oncological population burden of cardiac stress testing [5].

1.4 Cardiac Imaging and Its Guidelines

After 30 years of evolution, in the last 10 years stress echocardiography has reached its established rank in the diagnosis and prognosis of coronary artery disease, as officially certified by general cardiology [6, 7] and specialist guidelines [8, 9]. These guidelines unanimously conclude that nuclear cardiology and stress echocardiography provide

comparable information on key issues such as diagnostic accuracy for noninvasive detection of coronary artery disease, identification of myocardial viability, and prognostic stratification. In the recent American College of Cardiology (ACC)/American Heart Association (AHA) guidelines, the advantages listed for stress echocardiography include higher specificity, versatility, greater convenience, and lower cost. The advantages of stress perfusion imaging include higher technical success rate, higher sensitivity (especially for single-vessel disease involving the left circumflex artery), better accuracy when multiple resting left ventricular wall motion abnormalities are present, and a more extensive database in evaluation of the prognosis [6]. The European Society of Cardiology guidelines (2006) on stable angina conclude that "on the whole, stress echocardiography and stress perfusion scintigraphy, whether using exercise or pharmacological stress (inotropic or vasodilation), have very similar applications" [7]. However, the certified, comparable clinical performance cannot be construed as an argument for an opinion-driven choice of one technique over the other. The ACC /AHA Task Force (Committee on Management of Patients with Chronic Stable Angina) concluded that "the choice of which test to perform depends on issues of local expertise, available facilities and considerations of cost-effectiveness" [6]. The European Society of Cardiology concluded that "the choice as to which test is employed depends largely on local facilities and expertise." In the present era characterized by a quest for sustainability, the issues of relative cost (Fig. 1.8) [25], biological risk, and



Fig. 1.8 Relative costs of cardiac imaging. CT = cardiac tomography; SPECT = single photon emission computed tomography; CMR = cardiac magnetic resonance; PET = positron emission tomography (Adapted and modified from [25])

environmental impact of stress-testing procedures – not even mentioned in the guidelines – should be included in the decision-making process, not only for cardiac stress testing, but for every imaging test in all branches of medicine, as clearly recommended by the European Commission Medical Imaging guidelines [26].

1.5 Cardiac Imaging and the Radiation-Induced Biorisks

Small individual risks multiplied by billions of examinations become significant population risks [27–31]. At least 10% of all cancers are due to diagnostic imaging, and at least half of them come from cardiac examinations (Fig. 1.9). Cardiac stress imaging contributes to these individual and population biorisks. On the individual level, the effective dose is expressed in millisievert (mSv). It provides an estimate of the whole-body dose and a measure of the biological effects. The dose of a single nuclear cardiology procedure ranges from 27 mSv (>1,500 chest X-rays) from a thallium scan to 10 mSv (500 chest X-rays) from a technetium-MIBI scan [32–34]. One millisievert corresponds to the dose equivalent of 50 chest X-rays (single postero–anterior projection = 0.02 mSv). According to the latest estimation of BEIR VII (2006), this exposure dose corresponds to an extra-lifetime risk of cancer per examination ranging from 1 in 500 (thallium) to 1 in 1,000 (sestamibi) [35, 36]. The typical effective dose of several common diagnostic procedures is reported in Table 1.1



Fig. 1.9 Annual effective dose received by an average US inhabitant (from [23], National Council on Radiation Protection and Measurements). The total dose is of 3.2 mSv per year: 2.4 mSv from natural and 0.4 mSv from man-made sources. (Updated from [27])